Arthur Gelb is a Respiratory physician affiliated with University of California, Los Angeles. OpenAlex indexes 152 publications with 5,578 citations (h-index 39); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3650 South St
Suite 308
Lakewood, CA 907121502
Telephone
562-633-2275Registry record last updated 8 Jul 2007.
Clinical trials
- Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis
Sponsor: Gelb, Arthur F., M.D.
- Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
Sponsor: Gelb, Arthur F., M.D.
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Sponsor: Gelb, Arthur F., M.D.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
33 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year202531 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20259 payments
- Insmed, Inc.Program year202518 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
57.6%Corticosteroid38%Trelegy Ellipta70%Breo Ellipta12%Breztri Aerosphere9%Fluticasone Propionate6%Symbicort4%Part D<11 patientsbeta2-Adrenergic Agonist15.9%Albuterol Sulfate Hfa88%Ventolin Hfa12%Part D<11 patients+ 2 more classes in this area
Anti-infectives
11%Macrolide Antimicrobial7.8%Azithromycin100%Part D≥47 patientsPenicillins with extended spectrum3.1%Amoxicillin-Clavulanate Potass100%Part D≥23 patientsDermatology
9.3%Corticosteroid9.3%Methylprednisolone100%Part D≥54 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD
Respiratory Medicine
2013 - Unsuspected mild emphysema in nonsmoking patients with chronic asthma with persistent airway obstruction
Journal of Allergy and Clinical Immunology
2013 - Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I)
COPD Journal of Chronic Obstructive Pulmonary Disease
2012
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”